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Abstract
 
Minor histocompatibility antigens (mHAgs) present a significant impediment to organ and
bone marrow transplantation between HLA-identical donor and recipient pairs. Here we re-
port the identification of a new HLA-A
 
*
 
0201–restricted mHAg, HA-8. Designation of this
mHAg as HA-8 is based on the nomenclature of Goulmy (Goulmy, E. 1996. 
 
Curr. Opin. Im-
munol.
 
 8:75–81). This peptide, RTLDKVLEV, is derived from 
 
KIAA0020
 
, a gene of un-
known function located on chromosome 9. Polymorphic alleles of 
 
KIAA0020
 
 encode the al-
ternative sequences PTLDKVLEV and PTLDKVLEL. Genotypic analysis demonstrated that
the HA-8–specific cytotoxic T lymphocyte (CTL) clone SKH-13 recognized only cells that
expressed the allele encoding R at P1. However, when PTLDKVLEV was pulsed onto cells, or
when a minigene encoding this sequence was used to artificially translocate this peptide into
the endoplasmic reticulum, it was recognized by CTLs nearly as well as RTLDKVLEV. This
indicates that the failure of CTLs to recognize cells expressing the PTLDKVLEV-encoding al-
lele of 
 
KIAA0020
 
 is due to a failure of this peptide to be appropriately proteolyzed or trans-
ported. Consistent with the latter possibility, PTLDKVLEV and its longer precursors were
transported poorly compared with RTLDKVLEV by transporter associated with antigen pro-
cessing (TAP). These studies identify a new human mHAg and provide the first evidence that
minor histocompatibility differences can result from the altered processing of potential antigens
rather than differences in interaction with the relevant major histocompatibility complex mole-
cule or T cell receptor.
Key words: minor histocompatibility antigens • antigen processing • graft versus host disease • 
transplantation • Fourier transform mass spectrometry
 
Introduction
 
Bone marrow transplantation (BMT)
 
1
 
 is a crucial therapy
for hematological malignancies. Its therapeutic efficacy can
be attributed in part to the beneficial graft versus leukemia
effect in which residual host leukemic cells are eliminated
by mature donor-derived T cells present in the bone mar-
row inoculum (1). Although mature donor-derived T cells
facilitate graft acceptance, their reactivity against minor his-
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tocompatibility antigens (mHAgs) expressed by the recipi-
ent also leads to GVHD (2–9), and the administration of
immunosuppressive drugs after allogeneic bone marrow
transplants is essential to reduce morbidity and mortality (6,
10, 11).
mHAgs have been shown to be peptides derived from
normal cellular proteins that are presented by MHC class I
and II molecules (12, 13). Over 50 different mHAg genetic
loci have been defined among inbred strains of mice (14),
whereas the number in humans is unknown. Due to the
difficulty of identifying mHAg peptides, a full understand-
ing of the basis for minor antigenic disparities has yet to be
achieved. It is generally believed that identification of a
more extensive array of mHAg peptides and their cognate
genes will lead to improvements in pre-BMT donor and
recipient typing (15) and, in the more distant future, im-
munomodulatory strategies to decrease GVHD incidence
and severity as well as graft rejection.
The structure, genetics, and tissue distribution of several
human mHAgs have been studied by using specific T cells
isolated from allogeneic BMT patients (16–21). The use of
such T cells, together with either direct peptide extraction
and mass spectrometry (22–26) or cDNA cloning (21, 27),
has led to the successful identification of seven peptides
corresponding to human mHAgs. In this report, we de-
scribe the identification of the amino acid and nucleotide
sequences of an HLA-A
 
*
 
0201–restricted mHAg, termed
HA-8, as well as its negative polymorphic counterparts.
Our results provide the first evidence that the existence of
mHAg can result from altered processing of immunologi-
cally similar peptides rather than differences in interaction
with the relevant MHC molecule or T cell receptor.
 
Materials and Methods
 
Cell Culture. 
 
The HA-8 mHAg-specific, HLA-A
 
*
 
0201–
restricted CD8
 
1
 
 CTL clone (designated SKH-13 CTL) was de-
rived from the PBLs of a male patient who received a BMT from
his HLA-identical sister for chronic myelogenous leukemia. This
CTL clone was used in cytotoxicity and epitope reconstitution
assays either 11–15 d after stimulation as described previously
(28), or 1–3 d after thawing a frozen aliquot. HLA-A
 
*
 
0201
 
1
 
EBV–transformed B cell lines (BLCLs) include SDK (donor),
SKH (recipient), JY, RSR, JDR, Ruppen, and C1R-A2. BLCLs
from the Centre d’Étude du Polymorphisme Humain (CEPH)
(Paris, France; reference family 1362) were a gift from Dr. S.M.
Prescott and the Huntsman Cancer Institute, University of Utah
(Salt Lake City, UT). The TxB cell hybrids T1 and T2, which
are positive and negative for the transporter associated with anti-
gen processing (TAP), respectively, were obtained from Dr. P.
Cresswell (Yale University, New Haven, CT). BLCLs and hy-
brids were maintained in RPMI 1640 supplemented with 4 mM
Hepes, 5% FCS, 0.125% SerXtend (Irvine Scientific), and 3 mM
 
L
 
-glutamine (BLCL medium). In some experiments, the CEPH
BLCLs were infected with a recombinant vaccinia virus that en-
codes HLA-A
 
*
 
0201 (a gift of Dr. J. Yewdell, National Institute of
Allergy and Infectious Diseases, Bethesda, MD) at a multiplicity
of infection of 5:1, 18 h before use in cytotoxicity assays. High-
level cell surface expression of HLA-A2 was confirmed with flow
 
cytometry, and uninfected and wild-type vaccinia–infected cells
were used as controls.
 
Extraction and HPLC Fractionation of Immunoaffinity-purified,
HLA-A
 
*
 
0201–associated Peptides.
 
HLA-A
 
*
 
0201 molecules were
immunoaffinity purified from JY cells with mAb BB7.2 (29) and
their associated peptides were extracted as described previously
(25). The peptide extract was fractionated on a narrow bore HAI-
SIL C18 column (2.1 
 
3
 
 40 mm, 5 
 
m
 
m particles, 300 Å pore size;
Higgins) on 130A HPLC (Applied Biosystems). The elution gra-
dient used was 0–10% solvent B in 10 min, 10–60% B in the next
55 min, and 60–100% B in the next 7 min, where solvent A was
0.1% TFA (HPLC grade; Applied Biosystems) in NANOpure
water (Barnstead) and solvent B was 0.085% TFA in 60% acetoni-
trile (HPLC grade; Mallinckrodt) in NANOpure water. Fractions
were collected every 40 s at a flow rate of  200 
 
m
 
l/min. Active
fractions were pooled and rechromatographed with the identical
column and gradient, but using 0.1% heptafluorobutyric acid
(HFBA) as the ion-pairing agent. Half of the active second di-
mension material was used for a third dimension fractionation on
a microcapillary (30) column (280 
 
m
 
m outer diameter [OD], 75
 
m
 
m inner diameter [ID]) packed with 25 cm of 5 
 
m
 
m C18 beads
(YMC). TFA was used as the ion-pairing agent in buffers A and B
described above, and the column was eluted with a linear gradient
of 0–100% B over 40 min at a flow rate of 300 nl/min.
 
Epitope Reconstitution Assays. 
 
Aliquots of each HPLC frac-
tion were incubated with 2,000 
 
51
 
Cr-labeled, TAP-deficient T2
target cells and 7.5 
 
m
 
g/ml human 
 
b
 
2
 
-microglubulin (Calbio-
chem) for 30 min at 37
 
8
 
C in 150 
 
m
 
l BLCL medium. CTLs were
added in 100 
 
m
 
l BLCL medium at an E/T of 10:1 in a standard
 
51
 
Cr-release assay (22). Synthetic peptides were assayed using the
same protocol.
 
Peptide Analysis Using an Online Effluent Splitter and a Fourier
Transform Mass Spectrometer. 
 
Active third dimension HPLC
fractions were analyzed by electrospray ionization (ESI) on a
Fourier transform mass spectrometer
 
 
 
(FTMS) equipped with
nanoflow liquid chromatography and a modified online effluent
splitter (31–33). Samples were fractionated using a microcapillary
HPLC column (50 
 
m
 
m ID; reference 30) packed with 12 cm of 5
 
m
 
m C18 beads (YMC) and a 45-min gradient of 0–86% solvent
B (solvent A is 0.1 M acetic acid in water; solvent B is 0.1 M ace-
tic acid in 70% acetonitrile) flowing at 825 nl/min. The online
splitter directed 1/8 of the effluent to the FTMS for analysis and
7/8 into microtiter plate wells containing 25 
 
m
 
l NANOpure wa-
ter, which was reserved for epitope reconstitution assays.
 
Sequence Analysis of Candidate Antigens. 
 
Collision-activated
dissociation (CAD) mass spectra were recorded on selected pep-
tide candidates using a Finnigan LCQ ion trap MS equipped with
sheathless nanoflow HPLC-ESI as described previously (32). Data
were acquired by manually switching from MS-only mode to
MS/MS mode after the chromatographic elution of a marker
peptide. In MS/MS mode, the ion of interest was isolated using a
3.0 atomic mass unit isolation window and fragmented using 35%
collision energy. CAD spectra were analyzed in a manual search
of the GenBank/EMBL/DDBJ DNA and protein databases.
 
Synthetic Peptides. 
 
Peptides were synthesized on an AMS
1400 multiple peptide synthesizer (Gilson Medical Electronics)
using solid-phase FMOC chemistry and Wang resins. Peptides
were HPLC purified to 
 
.
 
98% on a C-8 column (Vydac). Purity
and identity of all synthetic peptides were confirmed using ESI
with an LCQ MS.
 
Class I Peptide-binding Affinity Assay. 
 
Relative affinities of
peptides for HLA-A
 
*
 
0201 molecules were measured as described 
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Brickner et al.
 
(34). In brief, affinity-purified HLA-A
 
*
 
0201 molecules were in-
cubated at room temperature with an 
 
125
 
I-labeled indicator pep-
tide (FLPSDYFPSV) and graded doses of test peptides in PBS,
pH 7.0, containing 0.05% NP-40, 1 
 
m
 
M human 
 
b
 
2
 
-microglubu-
lin (Calbiochem), 1 mM PMSF, 1.3 mM 1,10-phenanthroline, 73
 
m
 
M pepstatin A, 8 mM EDTA, and 200 
 
m
 
M 
 
N
 
a
 
-
 
p
 
-tosyl-
 
l
 
-lysine
chloromethyl ketone. After 48 h, class I peptide complexes were
separated from free peptides by gel filtration, and the dose of indi-
vidual test peptides that reduced the binding of indicator peptide
by 50% (IC
 
50
 
) was calculated.
 
Reverse Transcription PCR Amplification and Sequencing of the
KIAA0020 Region Encoding the HA-8 mHAg.
 
Poly(A)
 
1
 
 RNA
was isolated with a QuickPrep Micro mRNA Purification kit
(Amersham Pharmacia Biotech), and cDNA was synthesized us-
ing a First Strand cDNA synthesis kit (MBI Fermentas). Amplifi-
cations were performed with 0.5 
 
m
 
mol each of forward primer
 
5
 
9
 
-ATCAGAAGTTTTAAAGGCCAC-3
 
9
 
 and reverse primer
5
 
9
 
-GCTTCAATCATTTCTGATCTG-3
 
9
 
. Products were puri-
fied with the Wizard PCR Preps DNA purification system
(Promega) and cloned using the AdvanTAge cloning kit
(CLONTECH Laboratories, Inc.). At least five individual clones
were sequenced bidirectionally for each cell line examined.
 
Genotyping of HA-8 mHAg Polymorphisms. 
 
Genomic DNA
was isolated from BLCLs with a Puregene kit (Gentra Systems).
Adjacent intronic sequence required for genomic PCR analysis
was obtained from a genomic DNA library constructed by TA
cloning (35). Amplifications were performed with the allele-spe-
cific forward primers 5
 
9
 
-GTCAGCAGATCACCG-3
 
9
 
 (HA-8
 
R
 
)
and 5
 
9
 
-GTCAGCAGATCACCC-3
 
9
 
 (HA-8
 
P
 
 and HA-8
 
PL
 
), and
a common reverse primer 5
 
9
 
-GGGCAACAGTTATGGA-3
 
9
 
.
BLCLs were also genotyped using a modified PCR-RFLP tech-
nique (36). The forward primer 5
 
9
 
-GGATATACAGCA-
GAGCTTTC-3
 
9
 
 was used with the antisense primer 5
 
9
 
-
TCTAACACTTTGTCCCAGAATT-3
 
9
 
. The underlined A is
normally G in the 
 
KIAA0020
 
 sequence and was substituted such
that an EcoRI site is created only when the primer anneals to the
HA-8
 
R
 
 allele. PCR products were digested with EcoRI and ana-
lyzed on a 2.5% agarose gel. HA-8
 
P
 
 and HA-8
 
PL
 
 polymorphisms
produced a single 183-bp band, whereas the HA-8
 
R
 
 allele pro-
duced 165- and 22-bp bands.
 
Expression Plasmids Encoding the HA-8 mHAg and Its Homo-
logues. 
 
Minigene expression constructs encoding RTLDKV-
LEV, PTLDKVLEV, or PTLDKVLEV, with or without the ade-
novirus E3-19K endoplasmic reticulum (ER) insertion sequence
(37), were constructed using the pEAK10 vector (Edge Bio Sys-
tems). The constructs all encoded a Kozak sequence and initiator
methionine (AGCTTCCACCATG) and a stop codon (TTA).
All products were ligated into HindIII-NotI cut pEAK10 and
verified by sequencing. Additional expression plasmids were con-
structed that encoded truncated proteins corresponding to the
HA-8
 
R
 
, HA-8
 
P
 
, and HA-8
 
PL
 
 alleles. These initiate from the na-
tive start codon, include the peptides corresponding to the HA-8
mHAg and its alleles at residues 149–157, and terminate at the
predicted amino acid 223. Products containing these sequences
were reverse transcription (RT)-PCR amplified using a 5
 
9
 
 primer
containing a HindIII site, the native Kozak sequence and start
codon, and a 3
 
9
 
 primer containing the 
 
KIAA0020
 
 sequence up
 
Figure 1.
 
Reconstitution of the HA-8 mHAg epitope with HPLC-
fractionated peptides extracted from HLA-A
 
*
 
0201 molecules.
 
 
 
HLA-
A
 
*
 
0201–associated peptides were purified from 5 
 
3
 
 10
 
10
 
 JY cells and
fractionated by RP-HPLC as described in Materials and Methods. Ali-
quots of each fraction corresponding to 5 
 
3
 
 10
 
9
 
 cell equivalents were
preincubated with 
 
51
 
Cr-labeled T2 cells and tested for their ability to re-
constitute epitope activity for the SKH-13 CTL clone. An E/T ratio of
10:1 was used. (A) First dimension separation of extracted peptides was
achieved using TFA as the ion-pairing agent. (B) Fractions 42–44 from A
were pooled and rechromatographed using HFBA as the ion-pairing
agent. (C) Fractions 61 and 62 from B were pooled and rechromato-
graphed on a microcapillary column using TFA as the ion-pairing agent.
(D) Determination of candidate peptides via MS correlated with 51Cr-
release assay. Aliquots of each splitter fraction corresponding to 1.5 3 109
cell equivalents were incubated with 51Cr-labeled T2 target cells and
tested for their ability to reconstitute epitope activity as described in Ma-
terials and Methods. Ion abundances of candidate masses within the MS
scan window 520–560 were plotted and correlated to the percent specific
51Cr release in that same region. Background lysis of T2 by the CTLs in
the absence of any peptides was 7% in A, 2% in B, 1% in C, and 2% in D.
Positive control lysis was 91% in A, 98% in B, 96% in C, and 98% in D.198 Identification of the HA-8 Human Minor Histocompatibility Antigen
shown). By comparing the signal intensity of the naturally
occurring peptide with a known amount of synthetic
RTLDKVLEV, we calculated that this mHAg is present at
z10 copies per BLCL (data not shown). Target cells
pulsed with the RTLDKVLEV peptide were lysed by
SKH-13 CTLs, with half-maximal activity seen at a pep-
tide concentration of 20 pM (Fig. 2 C). RTLDKVLEV ad-
ditionally reconstitutes CTL lysis when incubated with
SDK, a BLCL derived from the HLA-identical sibling do-
nor (data not shown). Thus, RTLDKVLEV defines the
HLA-A*0201–restricted HA-8 mHAg epitope.
to nucleotide 1087, an in-frame stop codon, and a NotI site. All
constructs were introduced into SDK BLCLs by electroporation,
followed by incubation in BLCL medium for 48 h and selection
with puromycin (0.7 mg/ml; Edge Bio Systems) for an additional
48 h before use in cytolytic assays.
Streptolysin O Peptide Transport Assay. In vitro assays of TAP-
mediated peptide transport were performed as described previ-
ously (38), with modifications. T1 cells (106/sample) were per-
meabilized on ice for 15 min with streptolysin O (15 U/ml;
Murex Diagnostics) and incubated for 5 min at 378C with 100 ng
of the reporter peptide TVNKTERAY (reference 39; radiola-
beled with Na125I using the chloramine T method; reference 40),
10 ml 100 mM ATP, and indicated dilutions of competitor pep-
tides. The reporter peptide contains an N-linked glycosylation
site (Asn-X-Thr/Ser) and will become glycosylated after translo-
cation by TAP into the ER. Glycosylated reporter peptide was
isolated using Con A–Sepharose (Amersham Pharmacia Biotech),
eluted with 0.2 M methyl a-D-mannopyranoside (Sigma-Aldrich),
and quantitated on a g counter. Reporter peptide transport in
TAP-negative T2 cells was assessed as a negative control. Samples
were done in duplicate except for T2 negative control and T1
cells with no inhibitor, which were done in triplicate.
Results
Mass Spectrometric Identification of the HA-8 mHAg
Epitope.  To identify the mHAg recognized by CTL
clone SKH-13, HLA-A*0201–associated peptides were pu-
rified from the BLCL JY and fractionated by reverse phase
(RP)-HPLC. Fractions were analyzed for their ability to
reconstitute CTL recognition using TAP-deficient T2 cells
as target cells and the SKH-13 CTLs as effector cells in a
51Cr-release assay. Active fractions were pooled and carried
forward into another round of RP-HPLC under different
conditions. Single peaks of reconstituting activity were ob-
served through three rounds of fractionation (Fig. 1). Can-
didate masses for the HA-8 mHAg were identified by an
online effluent splitter analysis of the third dimension active
fractions using a combination of nanoflow liquid chroma-
tography with ESI on an FTMS (26). By comparing the
abundance of peptide ions in spectra from wells that
showed epitope reconstituting activity with SKH-13
CTLs, five candidate peptides were identified (Fig. 1 D).
The most abundant candidate ion (m/z 536.83412) was
analyzed by CAD on an LCQ MS, and its sequence was
determined to be RTXDKVXEV (Fig. 2, A and B). X
represents either Leu or Ile, amino acids of identical mass
that cannot be differentiated on the LCQ MS. To deter-
mine whether this sequence encoded the HA-8 mHAg,
the peptide was synthesized with an equimolar mixture of
Leu and Ile at each X position and tested for its ability to
sensitize T2 target cells to lysis by SKH-13 CTLs. Target
cells pulsed with RTXDKVXEV were lysed by SKH-13
CTLs, with half-maximal activity seen at a peptide con-
centration of z50 pM (Fig. 2 C). Of the four possible iso-
mers containing either Leu or Ile in place of X in this se-
quence, only the form containing Leu at both P3 and
P7 coeluted from a microcapillary HPLC column with
the naturally processed peptide m/z 536.83412 (data not
Figure 2. Identification of the HA-8 mHAg antigenic peptide. (A)
CAD mass spectrum of candidate peptide (M12H)21 ion with monoiso-
topic m/z of 536.83412 as eluted from JY BLCL. (B) CAD mass spectrum
of synthetic peptide RTLDKVLEV. Mass spectra were recorded on a
Finnigan LCQ ion trap MS operating with a 3.0 atomic mass unit isola-
tion window and 35% collision energy. The b and y ions (reference 54)
are labeled above and below the amino acid sequence, respectively. Ions
observed in the spectrum are underlined. (C) HA-8 mHAg epitope re-
constitution with synthetic peptides. A standard 51Cr-release assay was
performed by incubating the indicated quantities of synthetic peptides
with 51Cr-labeled T2 target cells and then adding the mHAg-specific
CTL clone SKH-13. An E/T ratio of 10:1 was used. FIDSYICQV corre-
sponds to the mHAg A2-HY (reference 25), and serves as a negative con-
trol. Background lysis of T2 by the CTLs in the absence of any peptides
was 4%; positive control lysis was 87%.199 Brickner et al.
The HA-8 mHAg Is Encoded by the Gene KIAA0020.
A search of the known protein and DNA sequence data-
bases with the sequence RTLDKVLEV generated a perfect
match with residues 149–157 of the predicted protein se-
quence of KIAA0020 (GenBank/EMBL/DDBJ accession
no. D13645; Fig. 3) and also to a predicted sequence
within a human expressed sequence tag (accession no.
AA307160; data not shown). AA307160 is identical to
KIAA0020 over 493 bp with the exception of four ambig-
uous nucleotides, and a single nucleotide insertion and de-
letion (data not shown). The latter appeared to be sequenc-
ing mistakes, since their effect was to encode multiple stop
codons in the same reading frame as the epitope sequence
upstream of the deletion and downstream of the insertion.
Thus, we hypothesized that KIAA0020 represents the gene
encoding the HA-8 mHAg. To definitively prove that
the KIAA0020 gene encodes HA-8, a 669-bp region of
KIAA0020 cDNA was cloned into a eukaryotic expression
vector and transiently transfected into SDK BLCL as de-
scribed in Materials and Methods. This transfectant was
recognized by SKH-13 CTLs (Fig. 4), thus conclusively
demonstrating that the HA-8 mHAg is encoded by
KIAA0020.
Identification of KIAA0020-related Sequences That Encode
Potential HA-8 mHAg Alleles.  To elucidate the basis for
differential expression of HA-8 within the human popula-
tion, we searched protein and DNA sequence databases
with the entire KIAA0020 coding sequence, and identified
three human homologues (Fig. 3). GenBank/EMBL/
DDBJ accesssion no. AC012407 exhibits low homology to
KIAA0020 in the epitope-flanking regions, and only 1/9
amino acids are identical in the epitope-analogous region.
More importantly, it has been mapped to chromosome 18,
whereas KIAA0020 maps to chromosome 9 (41). Thus,
AC012407 was excluded as a potential allele of KIAA0020,
although it may be a member of a gene family that includes
KIAA0020. In contrast, AA478933 and N90372 exhibited
.97.6% identity over .84 amino acid residues and are
predicted to encode RALDKVLEV and  PTLDKVLEV,
respectively, in the region homologous to the HA-8
mHAg epitope. Therefore, both AA478933 and N90372
were considered candidates for alleles of the KIAA0020
gene sequence.
RT-PCR primers (represented by black bars in Fig. 3)
that amplified a 347-bp cDNA product surrounding the
epitope were generated from sequences that were identical
among  KIAA0020,  AA307160, and AA478933 but not
conserved in the chromosome 18–encoded sequence.
Consistent with the finding that the HA-8 mHAg se-
quence RTLDKVLEV is encoded by KIAA0020, se-
quences identical to KIAA0020 were amplified from all
four BLCLs that were recognized by SKH-13 CTLs (Table
I). The only RT-PCR products amplified from the three
BLCLs not recognized by SKH-13 CTLs were identical to
N90372 (with the exception of two ambiguous nucleotides
in the N90372 sequence; Fig. 3). The absence of the
KIAA0020 sequence, together with the presence of the
N90372 sequence, is consistent with the hypothesis that
these represent alleles of the same gene. The polymorphic
nucleotide sequences corresponding to KIAA0020 and
N90372 were designated HA-8R and HA-8P, respectively.
The only RT-PCR products amplified from the HA-81
BLCL JY and Ruppen encoded HA-8R (Table I), whereas
both HA-8R and HA-8P were amplified from the HA-81
BLCL JDR. Interestingly, the amplification products of the
HA-82 BLCL SDK included not only HA-8P, but also a
second sequence with an additional nucleotide substitution.
This sequence again resulted in the substitution of P for R
at the P1 position in the epitope, whereas the additional
change led to the substitution of L for V at P9 (Table I).
This sequence was designated HA-8PL. HA-8PL has not
been observed in any of the other HA-82 cells that we
Figure 3. Alignment of the predicted protein sequence of the
KIAA0020 cDNA with those of homologous sequences found in Gen-
Bank/EMBL/DDBJ. Predicted amino acid differences are indicated in
bold type; bold X’s represent nucleotide sequence ambiguity. Predicted
epitope encoding and epitope analogous regions are indicated inside the
rectangle. Black bars indicate the positions of RT-PCR primers used to
amplify the 347-bp cDNA fragment described in the text and used subse-
quently for sequencing.
Figure 4. The human HA-8 mHAg epitope is encoded by the
KIAA0020 sequence represented in GenBank/EMBL/DDBJ under
accession no. D13645. A eukaryotic expression plasmid containing a 669-
bp region of the KIAA0020 cDNA encoding RTLDKVLEV was tran-
siently transfected into SDK (mHAg2 donor) BLCL as described in
Materials and Methods and incubated with the SKH-13 CTL clone in a
standard 51Cr-release assay. SKH is the BLCL of the mHAg1recipient.200 Identification of the HA-8 Human Minor Histocompatibility Antigen
have genotyped. However, SDK is the sibling and bone
marrow donor for SKH, and the products amplified from
SKH BLCL included both HA-8R and HA-8PL. Collec-
tively, these results are consistent with the hypothesis that
HA-8R, HA-8P, and HA-8PL are alleles of a single genetic
locus.
Further evidence for this hypothesis was obtained by
screening all individuals in three consecutive generations of
a large family for expression of the HA-8 mHAg, and cor-
relating the results with their genotype at the KIAA0020
locus. BLCLs derived from each individual in CEPH refer-
ence family 1362 were infected with a recombinant vac-
cinia virus expressing the HLA-A*0201 gene and tested for
HA-8 expression with SKH-13 CTLs (Fig. 5). The geno-
type of each individual at nucleotide 864 in the KIAA0020
cDNA sequence, which determines either an R or P in P1
of the epitope recognized by the SKH-13 CTL clone, was
determined by testing genomic DNA derived from each
BLCL with a PCR-RFLP assay that distinguishes between
G and C at this position. All HA-82 members of the CEPH
family 1362 exhibited the HA-8P sequence, whereas all
HA-81 members expressed both HA-8R and HA-8P (Fig.
5). These results confirm that the KIAA0020 gene has at
least two alleles, of which only HA-8R leads to specific
CTL recognition.
Effect of KIAA0020 Polymorphisms on CTL Recognition
and HLA-A*0201 Binding.  To gain further insight into
the mechanisms governing the lack of CTL recognition of
the cells of HA-82 individuals, we determined the relative
binding affinities of the three observed polymorphic pep-
tides for HLA-A*0201 (Fig. 6 A). RTLDKVLEV inhibited
the binding of an iodinated indicator peptide by 50% (IC50)
at a concentration of 40 nM, whereas PTLDKVLEV and
PTLDKVLEL bound 50-fold and 250-fold less well, re-
spectively. We next compared the ability of the three poly-
morphic peptides to reconstitute the epitope for the SKH-
13 CTL clone when exogenously pulsed onto target cells
(Fig. 6 B). SKH-13 CTL recognition of PTLDKVLEL re-
quired nearly 4,500-fold more peptide for half-maximal ly-
sis (z90 nM) than recognition of RTLDKVLEV (20 pM).
This difference is larger than the difference in HLA-
Table I. Correlation of KIAA0020 Sequence Polymorphisms with 
HA-8 Phenotype
HLA-A21
BLCLs
Polymorphism(s) encoded
by sequenced DNA
Cytolysis by
SKH-13 CTLs
JY RTLDKVLEV, RTLDKVLEV 1
Ruppen RTLDKVLEV, RTLDKVLEV 1
JDR RTLDKVLEV, PTLDKVLEV 1
SKH (recipient) RTLDKVLEV, PTLDKVLEL 1
SDK (donor) PTLDKVLEV, PTLDKVLEL 2
RSR PTLDKVLEV, PTLDKVLEV 2
C1R-A2 PTLDKVLEV, PTLDKVLEV 2
Figure 5. HA-8 mHAg allelic segregation analysis. Segregation of the
HA-8R and HA-8P alleles and correlation of the HA-8R allele with cytol-
ysis by SKH-13 CTLs at an E/T ratio of 5:1 is shown using the BLCL of
CEPH reference family 1362. Filled circles (females) or squares (males)
indicate strong lysis by SKH-13 CTLs (phenotype positive); open sym-
bols indicate minimal lysis (phenotype negative). Numbers below symbols
were assigned to each family member by the University of Utah. R/P
represents HA-8R/P heterozygous genotype; P/P represents HA-8P geno-
type (the HA-8P/liter polymorphism cannot be distinguished by these
genotyping PCR primers). Genotyping of HA-8 mHAg alleles was deter-
mined by PCR-RFLP of genomic DNA as described in Materials and
Methods.
Figure 6. HLA-A*0201 binding affinity of HA-8 mHAg peptide vari-
ants and SKH-13 CTL recognition of exogenously pulsed peptide vari-
ants. (A) Binding of RTLDKVLEV, PTLDKVLEV, and PTLDKVLEL
to HLA-A*0201. HPLC-purified synthetic peptides were assayed for their
ability to inhibit the binding of the iodinated peptide FLPSDYFPSV (r)
to affinity-purified HLA-A*0201 molecules in a cell-free peptide binding
assay (see Materials and Methods). (B) RTLDKVLEV, PTLDKVLEV,
and PTLDKVLEL were tested for their ability to reconstitute the epitope
for the SKH-13 CTL clone. Epitope reconstitution assay conditions are
described in Materials and Methods. An E/T ratio of 10:1 was used.
Background CTL lysis of T2 in the absence of any peptides was 4%; pos-
itive control lysis (SKH) was 80%.201 Brickner et al.
A*0201 binding affinity, suggesting that the substitutions at
P1 and P9 have an additional detrimental effect on CTL
recognition. However, recognition of PTLDKVLEV re-
quired only 15-fold more peptide (half-maximal lysis of
300 pM). Taking into account the differences in binding
affinity, this suggests that SKH-13 CTL recognizes PTLD-
KVLEV as well as or better than RTLDKVLEV. This
stands in contrast to the complete lack of recognition of
donor-derived (self) SDK BLCL cells or cells that are ho-
mozygous for HA-8P (Table I, Fig. 5, and data not shown).
These results suggested that differences in MHC binding
and CTL recognition did not account for the failure of
SKH-13 CTLs to recognize cells that were homozygous
for HA-8P and that differences in antigen processing might
instead be responsible.
Effect of KIAA0020 Polymorphisms on Antigen Process-
ing.  To address whether antigen processing might influ-
ence recognition by SKH-13 CTLs, KIAA0020 minigenes
encoding the HA-8R–, HA-8P–, and HA-8PL–derived pep-
tides were expressed transiently in SDK BLCL cells. The
minigene constructs used in these experiments resulted in
the peptides being produced in the cytosol or cotransla-
tionally translocated into the ER via the adenovirus E3-
19K signal sequence. Of the cytosolically translated mini-
genes, only the one encoding the HA-8R peptide was
recognized by SKH-13 CTLs (Fig. 7 A). A construct con-
taining a 669-bp fragment that encoded the HA-8P or HA-8PL
peptide in the context of a large cytosolically translated
product (analogous to that shown in Fig. 4) demonstrated
similar lack of recognition by SKH-13 CTLs (Fig. 7 B).
These observations correlate well with the data observed in
Table I and Fig. 5, which demonstrate recognition of only
those cells that express HA-8R. In contrast, SKH-13 CTLs
recognized cells expressing both HA-8R and HA-8P pep-
tides derived from minigenes that enabled direct transloca-
tion into the ER, although cells expressing HA-8PL in this
format were still not recognized (Fig. 7 A). The lack of rec-
ognition of cells transfected with the E3-19K–directed
HA-8PL construct likely reflects the lower HLA-A*0201
binding affinity of PTLDKVLEL relative to PTLDKVLEV.
However, the recognition of PTLDKVLEV by SKH-13
CTLs only when it is translocated into the ER via the E3-
19K signal sequence indicates that the lack of CTL recog-
nition of cells expressing the HA-8P encoding sequence
under normal circumstances is due to impaired TAP trans-
port of this peptide or to differences in cytosolic proteolysis
of its precursors.
To determine whether impaired TAP transport of
PTLDKVLEV-containing peptides could account for their
failure to be displayed by HLA-A*0201, we examined their
ability to be transported by TAP in vitro. Because the exact
peptides produced by cytosolic proteolysis are not known,
RTLDKVLEV, PTLDKVLEV, and versions of each pep-
tide containing one or five additional natural NH2-terminal
flanking amino acids were tested as substrates for their abil-
ity to inhibit TAP-dependent transport of the radiolabeled
reporter peptide TVNKTERAY in streptolysin O–perme-
abilized T1 cells (Fig. 8). RTLDKVLEV as well as the 10-
and 14-mer peptides containing this sequence were all
transported efficiently, exhibiting IC50 values in the range
of 30–45 mM. In contrast, PTLDKVLEV, HPTLDKV-
LEV, and KSADHPTLDKVLEV were transported consid-
erably less well, with IC50 values of 175, 355, and 102 mM,
respectively. Taken together, these data are consistent with
the hypothesis that impaired TAP translocation of HA-8P–
derived peptides accounts for the failure of endogenously
processed PTLDKVLEV to be recognized by HA-8
mHAg-specific CTLs.
Discussion
In this study, we identified the nonamer peptide RTLD-
KVLEV, represented within the KIAA0020 cDNA, as a
new HLA-A*0201–restricted mHAg, HA-8. KIAA0020 is
located on chromosome 9 and encodes a predicted protein
of 508 amino acids. Sequencing of cDNA from the BLCLs
of various HA-81 and HA-82 individuals also identified
Figure 7. Comparative SKH-13 CTL recognition of transiently trans-
fected KIAA0020 constructs. (A) CTL recognition of the donor-derived
BLCL SDK is shown after transient transfection of experimental minigene
constructs. Constructs tested contain a minigene cassette encoding the
KIAA0020 polymorphic peptides either with (closed symbols) or without
(open symbols) an E3-19K adenovirus leader peptide sequence, which di-
rects translocation of the expressed peptide to the ER, bypassing normal
TAP transport. CTL lysis of donor (SDK) and recipient (SKH) BLCL is
also shown. (B) Eukaryotic expression plasmids expressing a truncated
KIAA0020 protein initiating from the native start codon, encoding
RTLDKVLEV, PTLDKVLEV, or PTLDKVLEL without an E3-19K ad-
enovirus leader peptide sequence, were transiently transfected into SDK
BLCL as described in Materials and Methods and incubated with the
SKH-13 CTL clone in a standard epitope reconstitution assay. CTL lysis
of recipient (SKH) and donor (SDK) BLCL cells is indicated.202 Identification of the HA-8 Human Minor Histocompatibility Antigen
KIAA0020-related polymorphic sequences HA-8P and
HA-8PL, which encode the peptides PTLDKVLEV and
PTLDKVLEL, respectively. Based on inheritance patterns,
HA-8P is a bona fide allele of KIAA0020. We have yet to
demonstrate definitively that HA-8PL is also an allele of
KIAA0020, since this polymorphism was observed only in
one sibling pair, but its expression in both siblings suggests
that this is likely. In addition, database searches also iden-
tified an additional sequence with high homology to
KIAA0020 that encoded the predicted peptide RALDKV-
LEV. Because expression of the gene encoding this se-
quence was not observed in any BLCL, it remains to be
seen whether it also represents an allele of KIAA0020.
Nonetheless, the KIAA0020 polymorphisms associated
with HA-81 and HA-82 phenotypic expression most likely
represent at least a triallelic system. In contrast, only two al-
leles have been defined for the other known autosomal hu-
man mHAg HA-1 (24), HB-1 (27), and HA-2 (reference
22, and Pierce, R.A., and V.H. Engelhard, unpublished
data).
In principle, any genetic polymorphism that qualitatively
or quantitatively affects the display of self-peptides at the
cell surface could give rise to an mHAg disparity in an
MHC identical transplantation setting (13). These can be
classified based on their impact on either T cell recognition
or peptide presentation by MHC molecules. In the case of
the human mHAgs B7-HY (23) and A1-HY (26), and
mouse mHAg MTF (42), the mHAg2 alleles encode poly-
morphic peptides that retain their ability to bind to the rel-
evant MHC molecule. The existence of these mHAgs is
thus dependent on the presence within any individual of
TCR with an appropriate fine specificity to distinguish
mHAg-expressing cells from their negative counterparts. In
some cases, T cell discrimination may be augmented by the
presence of posttranslational modifications on the mHAg1
allelic peptides (25, 26). TCR discrimination between two
presented peptides has been proposed to define the human
HB-1 mHAg (27), the murine mHAgs H3a (43) and H13
(44), and the rat MTF mHAg (45). However, endogenous
presentation of the mHAg2 peptide has not been formally
demonstrated in any of these cases.
Two additional mechanisms in which the corresponding
negative allelic peptides are not presented at the cell surface
enable mHAgs to be distinguished by T cells. This type of
differential display may enable a more robust T cell re-
sponse, since it will not be limited to TCRs that can make
fine distinctions among closely related peptides. In one
case, mHAgs are distinguished due to polymorphisms that
diminish or abolish the ability of the mHAg2 peptide to
bind to the relevant MHC molecule. This mechanism un-
derlies the immunogenicity of the human mHAg HA-1
(24) and the murine mHAg HY-Db (46). A second possi-
bility is that the mHAg-positive and -negative peptides are
antigenically similar, but are handled differently by the an-
tigen processing machinery of the cell. Such a possibility
has not been previously described for mHAgs.
A critical observation in the present study is that HLA-
A*02011 cells expressing HA-8P and HA-8PL genes or
minigene fragments in the cytosol are not recognized by
SKH-13 CTLs, yet PTLDKVLEV as an exogenously
pulsed or ER translocated peptide is recognized nearly as
well as the HA-8 mHAg peptide RTLDKVLEV. This ob-
servation could indicate that either PTLDKVLEV or its
precursors are transported poorly by TAP, or that differ-
ences between the HA-8R and HA-8P protein products
lead either to a failure to produce the PTLDKVLEV
epitope or to its destruction by the proteasome or other
cellular proteases. It is noteworthy that in comparing the
cDNA sequences of a 347-bp region surrounding the
epitope in the seven HA-81 and HA-82 BLCLs listed in
Table I, the only polymorphisms were at the P1 and P9
positions within the epitope (data not shown). In addition,
the ability of PTLDKVLEV to be recognized by the SKH-
13 CTLs when targeted to the ER with an NH2-terminally
fused E3-19K signal sequence argues against substantial
degradation of this peptide by aminopeptidases in the ER
(47, 48). Differential proteolysis in the cytosol is one possi-
ble explanation for the failure of HA-82 cells to present
PTLDKVLEV. Previous studies have demonstrated that
subunit-independent proteasomal cleavage is augmented
three residues to the COOH terminal side of a P (49, 50).
This could result in greater destruction of the PTLDKV-
LEV epitope. On the other hand, we observed that PTLD-
KVLEV, as well as PTLDKVLEV-containing peptides with
additional natural NH2-terminal flanking amino acids, are
translocated into the ER in vitro appreciably less well than
RTLDKVLEV and its analogous NH2-terminally extended
peptides. This is consistent with previous studies showing
that peptides containing a P at P1 or P2 are generally trans-
ported poorly by human, mouse, and rat TAP (51–53),
whereas positively charged residues, and particularly R at
P1–P3, enhanced TAP interaction (52). It is interesting
that even in comparing the 14-mer peptides KSA-
DHPTLDKVLEV and KSADHRTLDKVLEV in this
Figure 8. In vitro transport of HA-8 mHAg peptide variants. T1 cells
were permeabilized with streptolysin O (15 U/ml) and incubated with
radioiodinated reporter peptide TVNKTERAY plus the indicated dilu-
tion of test peptides. Reporter peptide transport in TAP-negative T2 cells
was assessed as a negative control. Samples were done in duplicate except
for T2 negative control and T1 cells with no inhibitor, which were done
in triplicate.203 Brickner et al.
study, the presence of  P at P6 also diminished peptide
transport by TAP. Thus, while the exact epitope-contain-
ing substrates for TAP transport in vivo have not been
identified, our data suggest that those derived from HA-8P
and HA-8PL will be poorly transported by TAP. Taken to-
gether, our results suggest that the basis for lack of immu-
nogenicity of endogenous PTLDKVLEV lies not in differ-
ential recognition of the peptide by the HA-8–specific
TCR, but rather in its inability to be productively trans-
ported by TAP for presentation by HLA-A*0201 at the cell
surface. Thus, HA-8R represents the first mHAg that has
been shown to result from differential antigen processing
and this may represent an important mechanism for the
generation of mHAgs.
The elucidation of mHAg peptides and their cognate
genes forms a critical foundation for future attempts to im-
prove the outcome of MHC-identical, mHAg-mismatched
BMT, or solid organ transplants. The HA-8 mHAg is
present in the population at a phenotype frequency of
z65%. Additionally, HA-8 is presented by the HLA-
A*0201 restriction element, which has a high phenotype
frequency in most populations (i.e., 49% in the Caucasian
population). This suggests that BMT donor and recipient
pairs will often be discordant for this mHAg. Although the
significance of the HA-8 mHAg in GVHD or graft rejec-
tion remains to be determined, the genotyping reagents de-
scribed in this study will allow prospective studies of associ-
ation between HA-8 incompatibility and outcomes after
transplantation. The prospect of using the DNA sequences
encoding mHAgs in pre-BMT molecular typing to im-
prove donor selection or as a prognostic indicator of
GVHD/graft rejection risk becomes increasingly more at-
tainable with the identification of each new mHAg pep-
tide. In the more distant future, potential applications may
include tolerance induction in solid organ and bone mar-
row transplant and the design of prophylaxis against
GVHD and rejection.
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